US$ 20.42
retatrutide expected approval date FDA Status: July 2026 Update Retatrutide approval: FDA status, clinical
Description
, Wang, P

Both companies have requested the FDA add semaglutide and tirzepatide, respectively, to its lists of drug products that present demonstrable difficulties for compounding. These DDC Lists identify substances that are considered particularly risky to compound, and drugs on these lists cannot be compounded under either 503A or 503B which could be the biggest problem for companies like Hims

These reports suggest that GLP-1-based therapies have anti-inflammatory effects in the lung, testis, skin, and eye

Ozempic Vs
These are the timing mistakes people actually make, not hypothetical concerns, but real-world errors that affect real-world outcomes

Journal of Clinical Pharmacy and Therapeutics
